Uncategorized

Bayer and Kumquat Biosciences ink $1.3 billion deal to develop cancer inhibitor

HQ Team August 13, 2025: Bayer and Kumquat Biosciences, a clinical-stage biotech, announced an exclusive global license and collaboration agreement worth $1.3 billion.

Read More
Drugs Health Pharma

Bayer acquires marketing rights for heart drug in Europe for $310 million

HQ Team March 4, 2024: Bayer AG, a German multinational pharmaceutical and biotechnology company, has bought the marketing rights in Europe for a.

Read More